Incyte Co. (NASDAQ:INCY) Shares Bought by Veriti Management LLC

Veriti Management LLC raised its stake in Incyte Co. (NASDAQ:INCYGet Rating) by 10.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,040 shares of the biopharmaceutical company’s stock after purchasing an additional 1,311 shares during the period. Veriti Management LLC’s holdings in Incyte were worth $1,115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. National Asset Management Inc. raised its position in shares of Incyte by 5.3% during the 4th quarter. National Asset Management Inc. now owns 3,255 shares of the biopharmaceutical company’s stock worth $239,000 after acquiring an additional 164 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund raised its position in shares of Incyte by 3.7% during the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 4,810 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 170 shares in the last quarter. Glassman Wealth Services grew its stake in Incyte by 52.1% during the 4th quarter. Glassman Wealth Services now owns 502 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 172 shares during the last quarter. Mutual of America Capital Management LLC grew its stake in Incyte by 0.6% during the 4th quarter. Mutual of America Capital Management LLC now owns 27,650 shares of the biopharmaceutical company’s stock worth $2,030,000 after buying an additional 177 shares during the last quarter. Finally, State of Michigan Retirement System grew its stake in Incyte by 0.4% during the 4th quarter. State of Michigan Retirement System now owns 47,304 shares of the biopharmaceutical company’s stock worth $3,472,000 after buying an additional 200 shares during the last quarter. 92.78% of the stock is currently owned by institutional investors.

In related news, EVP Barry P. Flannelly sold 43,993 shares of the company’s stock in a transaction on Friday, April 8th. The stock was sold at an average price of $83.49, for a total value of $3,672,975.57. Following the completion of the transaction, the executive vice president now directly owns 65,163 shares in the company, valued at $5,440,458.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 15.80% of the company’s stock.

NASDAQ INCY opened at $73.75 on Thursday. Incyte Co. has a fifty-two week low of $61.91 and a fifty-two week high of $88.26. The stock has a market cap of $16.34 billion, a price-to-earnings ratio of 17.56, a price-to-earnings-growth ratio of 0.86 and a beta of 0.71. The business has a fifty day moving average of $74.97 and a 200-day moving average of $73.81. The company has a quick ratio of 3.67, a current ratio of 3.71 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCYGet Rating) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06. The firm had revenue of $733.20 million during the quarter, compared to analyst estimates of $753.54 million. Incyte had a return on equity of 12.77% and a net margin of 29.95%. The business’s quarterly revenue was up 21.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.50 earnings per share. As a group, analysts anticipate that Incyte Co. will post 2.31 EPS for the current year.

A number of research analysts recently issued reports on INCY shares. StockNews.com downgraded Incyte from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 14th. TheStreet downgraded Incyte from a “b” rating to a “c” rating in a research note on Tuesday, May 3rd. Morgan Stanley lifted their target price on Incyte from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 20th. Finally, Stifel Nicolaus lifted their price target on Incyte from $75.00 to $77.00 in a research note on Tuesday, May 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $87.09.

About Incyte (Get Rating)

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Stories

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCYGet Rating).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Want More Great Investing Ideas?

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.